Keryx Biopharmaceuticals Inc.


in
Keryx Biopharmaceuticals Inc. announced that as a result of cost-cutting initiatives resulting from the recent clinical failure of Sulonex, the company's Chief Accounting Officer, Mark Stier will resign effective June 30, 2008.